ISRCTN43372293
Completed
Phase 1
A Phase I, randomized, double-blind, placebo-controlled, dose-escalating clinical trial with KH176
Khondrion0 sites30 target enrollmentJune 27, 2017
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Khondrion
- Enrollment
- 30
- Status
- Completed
- Last Updated
- 7 years ago
Overview
Brief Summary
2017 results in: https://www.ncbi.nlm.nih.gov/pubmed/29037240
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Healthy as assessed by medical history, physical examination, vital signs, clinical laboratory, ECG
- •2\. Adult males
Exclusion Criteria
- •1\. Allergies
- •2\. Concomitant medication
- •3\. Concomitant disease
- •4\. Relevant surgery
- •5\. Recent blood donation
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Cisplatin Ototoxicity attenuated by ASpirin Trial (COAST)CancerISRCTN83689269Southampton University Hospitals NHS Trust (UK)88
Completed
Not Applicable
Studying the impact of Lorazepam on approach/avoidance behaviour in healthy individualsISRCTN12590498Psychiatric University Hospital (Psychiatrische Universitätsklinik) Zürich (PUK ZH)60
Completed
Phase 2
Study to evaluate the safety and efficacy of CCX168 in subjects with renal vasculitis on background cyclophosphamide treatmentRenal VasculitisCirculatory SystemRenal vasculitisISRCTN53663626ChemoCentryx, Inc. (USA)60
Completed
Not Applicable
A trial of Exenatide for the treatment of moderate severity Parkinson's diseaseTopic: Dementias and Neurodegenerative Diseases Research NetworkSubtopic: Parkinson?s DiseaseDisease: Parkinson's diseaseNervous System DiseasesParkinson diseaseISRCTN75891427niversity College London (UK)60
Completed
Phase 2
Innovations in the management of musculoskeletal pain with alpha-lipoic acidISRCTN58259979Physicians Services Incorporated Foundation27